Manufacturers: Sanofi
Riliprubart (SAR445088, BIVV020) is an investigational IgG4 humanized monoclonal antibody targeting activated C1s in the classical complement pathway, developed by Sanofi for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).
Riliprubart (SAR445088, BIVV020) is an investigational IgG4 humanized monoclonal antibody targeting activated C1s in the classical complement pathway, developed by Sanofi for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).
Riliprubart (SAR445088, BIVV020) is an IgG4 humanized monoclonal antibody that selectively inhibits activated C1s in the classical complement pathway of the innate immune system. By blocking C1s, riliprubart has the potential to inhibit key inflammatory mechanisms that drive demyelination and axonal damage in CIDP.
1 associated conditions
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
No patents found under this name
Patent documents usually refer to a drug by its chemical name or development code rather than its generic name, and applications are only published about 18 months after filing — so a newer drug may not appear here yet.
